Company Overview
ENDRA Life Sciences Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry where it develops specialized technologies to enhance clinical diagnostic ultrasound capabilities. The company's core business involves the creation of thermo-acoustic enhanced ultrasound technology, which utilizes a pulsed energy source comprising radio frequency to transmit energy deep into tissue for improved diagnostic imaging. In terms of scale, the company currently maintains a market capitalization of $6.51M and employs a workforce of 21 individuals. The reported annual revenue is listed as N/A in available financial records, while the market cap of $6.51M indicates that the company is a small-cap entity with limited public valuation relative to its operational footprint. This valuation metric suggests the company is in an early-stage development phase where market value is derived primarily from intellectual property potential rather than established sales performance or revenue generation.
Financial Health
The company reports a net income of $-8,007,205 and an EBITDA of $-8,392,886 over the trailing twelve months, while revenue data is listed as N/A. The substantial gap between the reported revenue figure (N/A) and the significant negative net income reveals a cost structure where operational expenses and research development costs far exceed any recognized sales, resulting in a loss-making operation. Free cash flow stands at $-4,490,133, which indicates that the company is consuming its available cash reserves to fund its operations and technology development rather than generating liquidity from its core business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability on a per-unit basis or has not recognized sales sufficient to calculate meaningful margins. Regarding liquidity, the company holds $794,036 in cash against total debt of $525,328, resulting in a debt-to-equity ratio of 306.53, which suggests a highly leveraged balance sheet relative to its equity base. Despite the high debt-to-equity ratio, the current ratio is 1.31, indicating that the company currently possesses sufficient current assets to cover its short-term liabilities without immediate liquidity distress. Return on Equity is reported at -236.3% and Return on Assets at -102.0%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and on the total asset base.
Valuation Assessment
The trailing twelve-month P/E ratio is 0.22, while the forward P/E is -0.94, a difference that implies the market expects earnings to remain negative or volatile in the coming year given the forward multiple is also negative. The price-to-book ratio stands at 19.95, which indicates that the market is valuing the company at a significant premium over its tangible book value, likely reflecting expectations of future technology monetization rather than current asset worth. Alternative valuation metrics such as price-to-sales are listed as N/A due to the lack of revenue data, while the EV/EBITDA ratio is -0.57, suggesting the company is being valued based on enterprise value relative to negative earnings generation. The stock has traded between a 52-week high of $11.96 and a 52-week low of $2.90, providing a context for price volatility over the last year. The beta value is -0.11, which is highly unusual for equity instruments and suggests an inverse correlation to the broader market or significant data anomalies affecting the volatility calculation relative to the S&P 500. These valuation figures combined with the negative earnings multiples highlight the speculative nature of the investment given the lack of positive earnings history.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which prevents a direct comparison of whether earnings are growing faster or slower than revenue due to the absence of baseline revenue figures. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources and retained earnings into growth initiatives such as research and development rather than distributing cash to shareholders. Since the company is a non-dividend payer, the capital that could otherwise be paid out is instead directed toward sustaining operations and funding the development of thermo-acoustic enhanced ultrasound technology. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, relying entirely on potential future technological breakthroughs to drive shareholder value.